Revolution Medicines (RVMD) EBIT Margin (2019 - 2023)

Revolution Medicines' EBIT Margin history runs 5 years deep, the most recent figure standing at 24256.47% for Q4 2023.

• In Q4 2023, EBIT Margin fell 2385394.0% year-over-year to 24256.47%; the TTM figure through Sep 2024 stood at 88031.94% (down 8662217.0% YoY), while the FY2023 annual figure was 4207.12%, down 347711.0% from the prior year.
• EBIT Margin was 24256.47% for Q4 2023 at Revolution Medicines, down from 2845.11% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 79.26% in Q1 2019 to a low of 24256.47% in Q4 2023.
• Historically, EBIT Margin has averaged 2109.23% across 5 years, with a median of 402.52% in 2022.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin soared 254813 bps in 2022, then sank 2385394 bps in 2023.
• A 5-year view of EBIT Margin shows it stood at 161.85% in 2019, then sank by 141 bps to 389.44% in 2020, then plunged by 44 bps to 559.33% in 2021, then increased by 28 bps to 402.52% in 2022, then plunged by 5926 bps to 24256.47% in 2023.
• The last three EBIT Margin figures came in at 24256.47% (Q4 2023), 2845.11% (Q2 2023), and 1071.53% (Q1 2023), per Business Quant data.